AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04890041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RA
Description: The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
Study NCT05181189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB+Omega-3
Description: The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
Study NCT05181189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAOIB+Placebo
Description: Placebo
Study NCT05237089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm\*40mm or 0.30mm\*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
Study NCT05237089 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22\*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
Study NCT05237089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
Study NCT05237089 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Health education
Description: The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
Study NCT05172934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial tenecteplase
Description: intra-arterial drug administered after mechanical thrombectomy
Study NCT05317117 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT
Description: The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.
Study NCT04744090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended.
Study NCT04744090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
Study NCT05065411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enobosarm & Abemaciclib Combo
Description: Subjects will receive a combo of Enobosarm \& Abemaciclib
Study NCT05065411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
Description: Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
Study NCT04727489 — intervention group
Intervention type: GENETIC
Intervention: DNA from subjects will be stored in the biobank of our study.
Description: Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.
Study NCT05366868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
Study NCT05366868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
Study NCT05366868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
Study NCT05194579 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PF-06881894 by on-body injector
Description: PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
Study NCT05194579 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PF-06881894 by prefilled syringe
Description: PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
Study NCT05387434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program-Remote (DPP-R)
Description: The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.
Study NCT05387434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program-Facebook (DPP-FB)
Description: The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
Study NCT05541796 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular lens
Description: Tecnis Symfony Optiblue (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate.~Tecnis Synergy™ IOL (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles.
Study NCT05322668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1)
Description: All the subjects will receive all the treatment in the same order.~On each hand 2 devices will be attributed as follow:~* Prototypes (812A-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812C-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812D-v1) will be applied on an area of the back of the patient's left hand, on healthy skin~* Prototypes (812F-v1) will be applied on an area of the back of the patient's left hand, on healthy skin
Study NCT05805319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: increasing total fiber intake
Description: Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake.
Study NCT06473038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction in Salt and Sugar
Description: 150 participants who are grouped under interventions, their data will be collected according to the alterations of sodium and sugar intake and then compared with the control group. Instruments include urine analysis, providing two spot urine samples - first-morning void and last void in the evening before leaving campus, at three-time points - at the start of the study, after 3 months, and after 6 months. This will yield a total of 300 × 2 × 3 = 1800 samples. Urine electrolytes (sodium, potassium, chloride) and creatinine will be measured using the potentiometry method (Alinity Abbott) at the laboratory department of Sunway Medical Centre, Bandar Sunway.
Study NCT06473038 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The potentiometer
Description: The potentiometer is utilized for the quantitative analysis of electrolytes present in urine samples. The potentiometer used for urine electrolytes analysis is a specialized device equipped with electrodes and sensors designed to detect and measure the concentration of specific electrolytes in urine samples. It employs potentiometric principles to generate electrical signals proportional to the concentration of ions present in the sample.
Study NCT06473038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Ashing Method Followed by Flame Atomic Absorption Spectrometry (FAAS)
Description: Dry ashing method involves heating the food samples in a controlled environment to remove organic matter and moisture, leaving behind inorganic residues (ashes) containing the salts and minerals present in the food. Flame Atomic Absorption Spectrometryis utilized to measure the levels of sodium and potassium (components of salt) as well as carbon and hydrogen (components of sugar) in the ashed food samples.~By determining the concentrations of these elements, the salt and sugar content of the food samples can be quantified accurately.
Study NCT03778164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Track Partner Services-Sexual Health Intervention
Description: The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
Study NCT03778164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partner Services Standard of Care
Description: Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
Study NCT05673941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative physical training
Description: The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
Study NCT05352581 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BD Veritor At-Home
Description: BD Veritor At-Home rapid self testing
Study NCT05352581 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BD Veritor Professional
Description: BD Veritor Professional rapid test
Study NCT06132139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisAR
Description: The study device is a Microsoft HoloLens which uses Novarad's proprietary software and is collectively known as VisAR.
Study NCT04677413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated radiotherapy for rectal cancer
Description: To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
Study NCT05083832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block
Description: Two different catheter techniques with same doses local anesthetic infusion
Study NCT05525806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials for MyProstateScore
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
Study NCT06109818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-488 Tablets
Description: ICP-488 will be administered as tablet
Study NCT06109818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-488 Placebo
Description: ICP-488 Placebo will be administered as tablet
Study NCT06109818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICP-488 Placebo
Description: ICP-488 Placebo will be administered as tablet
Study NCT06148324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTOR Program
Description: MENTOR is an online wellness program covering 11 wellness modules: Exercise; Nutrition; Mindfulness; Spiritual Practice; Self-Care; Arts \& Leisure; Rest \& Relaxation; Outdoors in Nature; Relationships; Core Values; and Contribution to Others.~The 8-week cycle comprises 40 hours of online group-based instruction and discussion, meeting up to five times per week.
Study NCT06092268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009 for injection ； Almonertinib Mesilate Tablets
Description: Phase IB: SHR-A2009 will be administered intravenously，Almonertinib Mesilate Tablets will be administered orally. 2 or 3 dose levels are preset in phase IB.~Phase II: 2 dose cohorts will be selected and it's randomization.
Study NCT06092268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009 for injection；Adebrelimab Injection
Description: Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy.
Study NCT06164639 — intervention group
Intervention type: BEHAVIORAL
Intervention: aspiration
Description: Based on whether the patient meets the diagnosis of aspiration pneumonia.
Study NCT06164639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: bronchial alveolar fluid
Description: Performing bronchoscopy.
Study NCT05283512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preventive treatment with IV-hydration
Description: IV hydration with isotonic 0.9% NaCl
Study NCT05283512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive treatment with oral hydration
Description: Oral hydration with regular bottled water
Study NCT05236088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation application
Description: It was applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device. It was applied for 30 minutes 3 days a week during 4 weeks
Study NCT05236088 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham neuromuscular electrical stimulation application
Description: Sham group will be applied from the same device, again 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
Study NCT05448443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD981
Description: Oral administration of AD981 in the morning and before sleep for 14 days
Study NCT05448443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo in the morning and before sleep for 14 days
Study NCT05256498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picostim Amber
Description: Picostim Amber temporary (24h) lead placement and extracorporeal stimulation
Study NCT05236699 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DEB-TACE combined with Surufatinib and Camrelizumab
Description: 1. All patients will be treated with standard DEB-TACE on the first day (D1).~2. After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~3. Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~4. The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study.
Study NCT05927337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for managing Obesity
Description: Patients included in the intervention group will be treated with a tailored cognitive behavioural therapy programme for obesity management. The programme is designed and adapted from the Individualised Cognitive Behavioural Therapy for Obesity Management programme (Dalle Grave et al., 2018), which is divided into six content modules aimed at weight loss and weight maintenance. For the purpose of the research, an abbreviated programme will be designed and used, and the content modules will remain the same as in the original version of the programme.
Study NCT06153719 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12-weeks combined exercise intervention
Description: This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
Study NCT06153719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-weeks combined exercise intervention
Description: This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
Study NCT05928546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: Intra-pocket application of quercetin nanoemulgel :~* After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~* That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket .
Study NCT05928546 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing
Description: - Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
Study NCT05928546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: - Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
Study NCT06120829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
Study NCT06120829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
Study NCT06120829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Needle Biopsy
Description: Core Needle Biopsy
Study NCT05262829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Mesenchymal Stem Cells
Description: MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection